Exemed to acquire UCB Pharma’s Indian production facility

Hannah Blake

pharmaphorum

UCB Pharma has announced that Exemed Pharmaceuticals, a fast-growing Indian manufacturing company, will acquire UCB’S Indian production facility in Vapi. The deal includes a multi-year supply agreement between UCB and Exemed, as well as the transfer of UCB Vapi’s 80 members of staff to Exemed.

UCB’s Vapi facility focuses on the production, packaging and distribution of some of UCB’s mature drugs, mainly for the pharmaceutical market in India, and produces less than 2% of total UCB volumes. Exemed will continue this production, but plans to also bring new business to the site.

The agreement is in line with UCB’s current strategy to focus on bringing new innovative drugs to patients, moving away from mass manufacturing.

The financial details of the deal have not been disclosed. However, UCB has stated that this transaction will not impact its financial guidance for 2012.

Euro-Africa-health-Investment-March-26-27-2013

Related news:

UCB : to enter into an asset purchasing agreement with Exemed Pharmaceuticals for its Indian manufacturing facility (4-traders)

Reference links:

UCB Pharma press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.